NCT07632157
MAGNEsium With meToprolol for Rate Control In Atrial Fibrillation
Not Yet Recruiting
PHASE3Ages 18+InterventionalTreatmentWake Forest University Health SciencesInvestigator-initiated
~196 participants
Updated 2026-06-29 on ClinicalTrials.gov
What's tested:Magnesium Sulfate 2gMagnesium Sulfate 4gSaline (0.9% NaCl)
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Ventricular rate control
Measured over Within the first 2 hours of intravenous magnesium administration
Conditions
Where it's being run
1 sites across 1 statesIllinois1
Study leadership
- Marc McDowell, PharmD · PRINCIPAL_INVESTIGATOR · Advocate Christ Medical Center Emergency Department
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Age \> 18 years or older
Able to provide informed consent
Primary diagnosis atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR) greater than or equal to 120 beats per minute
Metoprolol as rate control agent
English speaking
Exclusion
Hemodynamically unstable patients (SBP \<90, MAP \<65)
Impaired consciousness
Acute heart failure exacerbation based on clinical diagnosis, physician exam, bedside echo, and/or additional imaging
Patient in AFF RVR that is highly suspected to be a compensatory mechanism for an alternative clinical diagnosis
Rhythms other than atrial fibrillation, such as sick sinus syndrome or wide-complex ventricular response
Acute myocardial infarction
Contraindications to magnesium sulfate (including myasthenia gravis)
Allergy or sensitivity to any study drugs
Previously enrolled in this trial during a different patient encounter
Withdrew from study
What this trial measures
- Ventricular rate controlWithin the first 2 hours of intravenous magnesium administration
Assessing ventricular rate control within the first 2 hours of intravenous magnesium administration as defined as a ventricular rate of \< 120 beats per minute.